TICKERNERD
Menu
VERAVERAHealthcare · Biotechnology

VERA Stock Forecast: Vera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$34
−0.79% on the day

The 14 Wall Street analysts covering Vera Therapeutics, Inc. hold a median 12-month price target of $82 — +139.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 18 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.5B
Ticker Nerd rank
28 / 100
Median analyst target
$82
Analysts covering
14
Revenue$0.0
Operating income−$112.5M
Net income−$109.5M
Free cash flow−$100.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
+5.3%
YTD
−32.9%
1Y
+29.1%
From 52W high
−38.9%
From 52W low
+41.1%
$24
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
63
Momentum
59
Accruals
56
Value
50
Issuance
45
Revisions
36
Size
33
Quality
33
Growth
23

Volatility (63): The share price has been relatively steady.

Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26VERAHigh $100Median $82Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $34Median $82High $100

The green dot is the last close — the median target sits +139.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
8 Sept 2026JP MorganMaintainsOverweight$76 → $83
17 Aug 2026WedbushReiteratesNeutral$34
17 Aug 2026WedbushReiteratesNeutral—
12 Aug 2026HC Wainwright & Co.MaintainsBuy$125 → $90
12 Aug 2026HC Wainwright & Co.MaintainsBuy—
11 Aug 2026WedbushMaintainsNeutral—
11 Aug 2026WedbushMaintainsNeutral$43 → $34
8 July 2026GuggenheimMaintainsBuy$56 → $76
8 July 2026GuggenheimMaintainsBuy—
8 July 2026HC Wainwright & Co.MaintainsBuy—
8 July 2026HC Wainwright & Co.MaintainsBuy$110 → $125
8 July 2026TD CowenMaintainsBuy—
8 July 2026TD CowenMaintainsBuy$73 → $78
8 July 2026WedbushMaintainsNeutral$35 → $43
8 July 2026WedbushMaintainsNeutral—
7 July 2026B of A SecuritiesMaintainsBuy$65 → $70
7 July 2026B of A SecuritiesMaintainsBuy—
15 May 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026Wolfe ResearchUpgradeOutperform—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VERA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Vera Therapeutics, Inc. returned +29.1% against +16.3% for the S&P 500, dividends included.

VERA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26VERAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

Vera Therapeutics, Inc. (VERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.4×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
6.0×

Cheaper than 16% of US stocks

EV / EBITDA
−4.9×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−91.8%

Higher than 14% of US stocks

Return on assets
−46.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vera Therapeutics, Inc. (VERA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vera Therapeutics, Inc. has a market value of $2.5B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$401.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$339.2M.

  • Shares outstanding: 72.0M.

  • Trailing P/E: −7.4×; forward P/E: −7.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vera Therapeutics, Inc. employs 361 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

VERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERAVera Therapeutics, Inc.$2.5B
28
HRMYHarmony Biosciences Holdings, Inc.$2.4B
85
VRDNViridian Therapeutics, Inc.$2.4B
47
SLSSELLAS Life Sciences Group, Inc.$2.3B
64
MLYSMineralys Therapeutics, Inc.$2.5B
25
PHVSPharvaris NV$2.5B
42
AUPHAurinia Pharmaceuticals, Inc.$2.2B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VERA news & analysis

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Vera Therapeutics, Inc. (VERA) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The item reports that the company participated in this investor conference event. The presentation gives Vera Therapeutics a platform to communicate with investors and industry participants at a major healthcare conference, which can raise visibility for the company among the investment community.

Why it matters — Vera watchers would care because presenting at a major investment conference gives the company direct exposure to institutional investors and analysts who follow the biotech space.

What's Going on With Vera Therapeutics Stock on Tuesday?

Benzinga · 15 Sept 2026neutral

Vera Therapeutics shares traded lower on Tuesday after initially spiking higher, amid increased volatility following the company's announcement of data from the ORIGIN 3 trial.

Why it matters — A Vera Therapeutics watcher would care because the ORIGIN 3 trial data announcement triggered significant volatility in the stock on Tuesday.

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Barrons · 15 Sept 2026positive

Vera Therapeutics is advancing toward full FDA approval for its injectable kidney drug, Trutakna, following new trial results. The news drove the company's stock higher.

Why it matters — Vera Therapeutics' progress toward full FDA approval of Trutakna is significant because securing regulatory clearance for its key kidney drug could be a major catalyst for the company.

Why is Vera Therapeutics stock reversing its premarket gains?

Invezz · 15 Sept 2026positive

Vera Therapeutics shares rose in premarket trading on September 15 after the company announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

Why it matters — A VERA watcher would care because positive Phase 3 efficacy data for its lead therapy could be a significant milestone for the company's pipeline and its treatment for IgA nephropathy.

Vera Stock Slides Despite Positive Phase 3 Results

Schaeffers Research · 15 Sept 2026neutral

Vera Therapeutics shares fell 2% to $33.34, reversing earlier gains after the company disclosed positive late-stage ORIGIN 3 trial results for its TRUTAKNA drug.

Why it matters — The news is significant because it highlights the market's reaction to positive late-stage trial results for Vera's key TRUTAKNA drug, a major development for the company.

FAQ

Frequently asked questions about VERA stock

What is the VERA stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Vera Therapeutics, Inc. have a median 12-month price target of $82, with estimates ranging from $34 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERA stock a buy right now?

Of the 14 analysts covering Vera Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vera Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERA?

As at 18 Sept 2026, Vera Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).

Will VERA stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +139.7% from the last close, and Ticker Nerd's factor model ranks Vera Therapeutics, Inc. 28 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERA stock forecast for 2030?

No analyst covering Vera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $100 over the next 12 months.

How has VERA stock performed over the past year?

Vera Therapeutics, Inc. returned +29.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vera Therapeutics, Inc. do?

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases.

What is the latest news on VERA?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Vera Therapeutics, Inc. (VERA) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The item reports that the company participated in this investor conference event. The presentation gives Vera Therapeutics a platform to communicate with investors and industry participants at a major healthcare conference, which can raise visibility for the company among the investment community.

Company

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics operates in the biotechnology and health technology sectors, where its work targets conditions driven by abnormal immune activity and unmet medical needs. Headquartered in Brisbane, California, the company’s business today is centered on advancing immunology-focused drug candidates through clinical development and toward commercialization.

CEO Dr. Marshall W. Fordyce M.D. · 361 employees · United States · https://veratx.com